Skip to main content
Erschienen in: European Radiology 11/2016

30.03.2016 | Oncology

Predicting EGFR mutation status in lung cancer:Proposal for a scoring model using imaging and demographic characteristics

verfasst von: Ali Sabri, Madiha Batool, Zhaolin Xu, Drew Bethune, Mohamed Abdolell, Daria Manos

Erschienen in: European Radiology | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

To determine if a combination of CT and demographic features can predict EGFR mutation status in bronchogenic carcinoma.

Methods

We reviewed demographic and CT features for patients with molecular profiling for resected non-small cell lung carcinoma. Using multivariate logistic regression, we identified features predictive of EGFR mutation. Prognostic factors identified from the logistic regression model were then used to build a more practical scoring system.

Results

A scoring system awarding 5 points for no or minimal smoking history, 3 points for tumours with ground glass component, 3 points for airbronchograms, 2 points for absence of preoperative evidence of nodal enlargement or metastases and 1 point for doubling time of more than a year, resulted in an AUROC of 0.861. A total score of at least 8 yielded a specificity of 95 %. On multivariate analysis sex was not found to be predictor of EGFR status.

Conclusions

A weighted scoring system combining imaging and demographic data holds promise as a predictor of EGFR status. Further studies are necessary to determine reproducibility in other patient groups. A predictive score may help determine which patients would benefit from molecular profiling and may help inform treatment decisions when molecular profiling is not possible.

Key points

EGFR mutation-targeted chemotherapy for bronchogenic carcinoma has a high success rate.
Mutation testing is not possible in all patients.
EGFR associations include subsolid density, slow tumour growth and minimal/no smoking history.
Demographic or imaging features alone are weak predictors of EGFR status.
A scoring system, using imaging and demographic features, is more predictive.
Literatur
1.
Zurück zum Zitat Canadian Cancer Society (2014) Canadian cancer statistics 2014. Canadian Cancer Society, Toronto, Ontario. Available via http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2014-EN.pdf. Accessed 20 July 2015 Canadian Cancer Society (2014) Canadian cancer statistics 2014. Canadian Cancer Society, Toronto, Ontario. Available via http://​www.​cancer.​ca/​~/​media/​cancer.​ca/​CW/​cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2014-EN.pdf. Accessed 20 July 2015
2.
Zurück zum Zitat Canadian Cancer Society (2015) Lung cancer. Canadian Cancer Society, Toronto, Ontario. Available at http://www.cancer.ca/en/cancer-type/lung/statistics/?region=on.Accessed. Accessed 26 July 2015 Canadian Cancer Society (2015) Lung cancer. Canadian Cancer Society, Toronto, Ontario. Available at http://​www.​cancer.​ca/​en/​cancer-type/​lung/​statistics/​?​region=​on.​Accessed.​ Accessed 26 July 2015
4.
Zurück zum Zitat Lee DH, Srimuninnimit V, Cheng R, Wang R, Orlando M (2015) Epidermal growth factor receptor mutation status in the treatment of Non- small cell lung cancer: lessons learned. Cancer Res Treat(Apr 29) Lee DH, Srimuninnimit V, Cheng R, Wang R, Orlando M (2015) Epidermal growth factor receptor mutation status in the treatment of Non- small cell lung cancer: lessons learned. Cancer Res Treat(Apr 29)
5.
Zurück zum Zitat Mak RH, Digumarthy SR, Muzikansky A et al (2011) Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist 16(3):319–26CrossRefPubMedPubMedCentral Mak RH, Digumarthy SR, Muzikansky A et al (2011) Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist 16(3):319–26CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Zhu CQ, Da Cunha Santos G, Ding K, et al (2008) Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 10; 26 (26):4268-75 Zhu CQ, Da Cunha Santos G, Ding K, et al (2008) Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 10; 26 (26):4268-75
7.
Zurück zum Zitat Suzuki M, Shigematsu H, Hiroshima K et al (2005) Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol 36(10):1127–34CrossRefPubMed Suzuki M, Shigematsu H, Hiroshima K et al (2005) Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol 36(10):1127–34CrossRefPubMed
8.
Zurück zum Zitat Tomita M, Ayabe T, Chosa E, Kawagoe K, Nakamura K (2014) Epidermal growth factor receptor mutations in Japanese men with lung adenocarcinomas. Asian Pac J Cancer Prev 15(24):10627–30CrossRefPubMed Tomita M, Ayabe T, Chosa E, Kawagoe K, Nakamura K (2014) Epidermal growth factor receptor mutations in Japanese men with lung adenocarcinomas. Asian Pac J Cancer Prev 15(24):10627–30CrossRefPubMed
9.
Zurück zum Zitat Shi Y, Au JS, Thongprasert S et al (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 9(2):154–62CrossRefPubMedPubMedCentral Shi Y, Au JS, Thongprasert S et al (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 9(2):154–62CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958–67CrossRefPubMed Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958–67CrossRefPubMed
11.
Zurück zum Zitat Hirsh V, Melosky B, Goss G, Morris D, Morzycki W (2012) A personalized approach to treatment: use of egfr tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada. Curr Oncol 19(2):78–90CrossRefPubMedPubMedCentral Hirsh V, Melosky B, Goss G, Morris D, Morzycki W (2012) A personalized approach to treatment: use of egfr tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada. Curr Oncol 19(2):78–90CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Yano S, Yamada T, Takeuchi S et al (2011) Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 6(12):2011–7CrossRefPubMed Yano S, Yamada T, Takeuchi S et al (2011) Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 6(12):2011–7CrossRefPubMed
13.
Zurück zum Zitat Lee Y, Lee HJ, Kim YT et al (2013) Imaging characteristics of stage I non-small cell lung cancer on CT and FDG-PET: relationship with epidermal growth factor receptor protein expression status and survival. Korean J Radiol 14(2):375–83CrossRefPubMedPubMedCentral Lee Y, Lee HJ, Kim YT et al (2013) Imaging characteristics of stage I non-small cell lung cancer on CT and FDG-PET: relationship with epidermal growth factor receptor protein expression status and survival. Korean J Radiol 14(2):375–83CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Sugano M, Shimizu K, Nakano T et al (2011) Correlation between computed tomography findings and epidermal growth factor receptor and KRAS gene mutations in patients with pulmonary adenocarcinoma. Oncol Rep 26(5):1205–11PubMed Sugano M, Shimizu K, Nakano T et al (2011) Correlation between computed tomography findings and epidermal growth factor receptor and KRAS gene mutations in patients with pulmonary adenocarcinoma. Oncol Rep 26(5):1205–11PubMed
15.
Zurück zum Zitat Hsu KH, Chen KC, Yang TY et al (2011) Epidermal growth factor receptor mutation status in stage I lung adenocarcinoma with different image patterns. J Thorac Oncol 6(6):1066–72CrossRefPubMed Hsu KH, Chen KC, Yang TY et al (2011) Epidermal growth factor receptor mutation status in stage I lung adenocarcinoma with different image patterns. J Thorac Oncol 6(6):1066–72CrossRefPubMed
16.
Zurück zum Zitat Rizzo S, Petrella F, Buscarino V, et al (2015 May 9) CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer. Eur Radiol. [Epub ahead of print] Rizzo S, Petrella F, Buscarino V, et al (2015 May 9) CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer. Eur Radiol. [Epub ahead of print]
17.
Zurück zum Zitat Hsu JS, Huang MS, Chen CY et al (2014) Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma. J Thorac Imaging 29(6):357–63CrossRefPubMed Hsu JS, Huang MS, Chen CY et al (2014) Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma. J Thorac Imaging 29(6):357–63CrossRefPubMed
18.
Zurück zum Zitat Lindeman NI, Cagle PT, Beasley MB et al (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the college of american pathologists, international association for the study of lung cancer, and association for molecular pathology. J Thorac Oncol 8(7):823–59CrossRefPubMedPubMedCentral Lindeman NI, Cagle PT, Beasley MB et al (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the college of american pathologists, international association for the study of lung cancer, and association for molecular pathology. J Thorac Oncol 8(7):823–59CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Choi CM, Kim MY, Hwang HJ et al (2015) Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation. Radiology 275:1CrossRef Choi CM, Kim MY, Hwang HJ et al (2015) Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation. Radiology 275:1CrossRef
20.
Zurück zum Zitat Chang B, Hwang JH, Choi YH et al (2013) Natural history of pure ground-glass opacity lung nodules detected by low-dose CT scan. CHEST 143:172–178CrossRefPubMed Chang B, Hwang JH, Choi YH et al (2013) Natural history of pure ground-glass opacity lung nodules detected by low-dose CT scan. CHEST 143:172–178CrossRefPubMed
21.
Zurück zum Zitat Oda S, Awai K, Murao K et al (2011) Volume-doubling time of pulmonary nodules with ground glass opacity at multidetector CT: Assessment with computer-aided three-dimensional volumetry. Acad Radiol 18:63–69CrossRefPubMed Oda S, Awai K, Murao K et al (2011) Volume-doubling time of pulmonary nodules with ground glass opacity at multidetector CT: Assessment with computer-aided three-dimensional volumetry. Acad Radiol 18:63–69CrossRefPubMed
22.
Zurück zum Zitat Lynch JA, Khoury MJ, Borzecki A et al (2013) Epidermal growth factor receptor (EGFR) test utilization in the united states: a case study of T3 translational research. Genet Med 15(8):630–638CrossRefPubMedPubMedCentral Lynch JA, Khoury MJ, Borzecki A et al (2013) Epidermal growth factor receptor (EGFR) test utilization in the united states: a case study of T3 translational research. Genet Med 15(8):630–638CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat European Lung Cancer Conference (2015) LBA2_PR EGFR mutation testing and oncologist treatment choice in advanced NSCLC: Global trends and differences. Available via www.ESMO.org Accessed November 20, 2015 European Lung Cancer Conference (2015) LBA2_PR EGFR mutation testing and oncologist treatment choice in advanced NSCLC: Global trends and differences. Available via www.​ESMO.​org Accessed November 20, 2015
Metadaten
Titel
Predicting EGFR mutation status in lung cancer:Proposal for a scoring model using imaging and demographic characteristics
verfasst von
Ali Sabri
Madiha Batool
Zhaolin Xu
Drew Bethune
Mohamed Abdolell
Daria Manos
Publikationsdatum
30.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 11/2016
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-016-4252-3

Weitere Artikel der Ausgabe 11/2016

European Radiology 11/2016 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.